It distributes evenly in the heart and kidney, efficiently blocks mineralocorticoid receptor (MR) activity at lower doses, and has less interference with glucocorticoid and androgen receptors, potentially reducing adverse effects like gynecomastia or sexual dysfunction (14–16). Here, NR3C2 is linked to Gynecomastia.